the results suggest that the additional cholesterol reducing action of clofibrate in patients with hyperlipoproteinemia type iia who have already been treated by diet is mainly achieved by the reduction of ldl-cholesterol , the atherogenic properties of which are well known .
C0008377
cholesterol
C0023824
ldl-cholesterol